Bone Marrow Aplasia Under Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: A Rare and Unpredictable Complication.
5 affiliations
- 1Hematology, Centre Hospitalier Universitaire Mohammed VI, Agadir, MAR.
- 2Clinical Hematology and Cellular Therapy, Centre Hospitalier Universitaire Mohammed VI, Agadir, MAR.
- 3Hematology, Hôpital Universitaire de Bruxelles (HUB) Institut Jules Bordet, Bruxelles, BEL.
- 4Hematology, Ibn Zohr University, Medical School of Agadir, Agadir, MAR.
- 5Hematology, Faculté de Médecine et de Pharmacie Agadir, Agadir, MAR.
Abstract
Tyrosine kinase inhibitor (TKI)-induced bone marrow aplasia is a rare but potentially severe complication of chronic myeloid leukemia (CML). We report two cases occurring under imatinib and nilotinib in patients with chronic-phase CML. The first case, occurring six months after imatinib initiation, was characterized by severe bone marrow aplasia associated with gelatinous marrow transformation, a rare histological finding in TKI-treated CML. The second case, occurring two months after switching to nilotinib, evolved toward non-severe bone marrow aplasia, with complete hematologic recovery after treatment discontinuation. These observations illustrate the heterogeneity and unpredictability of this toxicity, which may occur across different TKI generations and levels of molecular response. Immediate TKI discontinuation remains essential, and any persistent pancytopenia should prompt early bone marrow evaluation to ensure a timely diagnosis and appropriate management.
Related
- Extranodal Organ Involvement in Chronic Lymphocytic Leukemia: Clinical Features and Outcomes With Bruton Tyrosine Kinase and BCL‐2 Inhibitors
- The role of tyrosine kinase inhibitors as a post-hematopoietic stem cell transplant continuation therapy for pediatric acute leukemia: a systematic review
- HEALTH-RELATED QUALITY OF LIFE AND HEALTH UTILITY AMONG BRAZILIAN PATIENTS WITH CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA RECEIVING TYROSINE KINASE INHIBITORS: REAL-WORLD EVIDENCE FROM BRAZIL
- Factors Influencing the Treatment Response of Tetracyclines for Papulopustular Rash Induced by Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors: A Retrospective Study.
- Therapeutic Impact of Third-generation Tyrosine Kinase Inhibitors on Lung Squamous Cell Carcinoma with Epidermal Growth Factor Receptor Mutations: A Case Description and Systematic Literature Review
BibTeX
@article{annasser2026bone,
title = {{Bone Marrow Aplasia Under Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: A Rare and Unpredictable Complication.}},
author = {Morad Annasser and Omar Halloumi and Rida Fatima Ezzahra and Salma Fares},
journal = {Cureus},
year = {2026},
month = sep,
doi = {10.7759/cureus.117060},
url = {https://europepmc.org/article/MED/42953131},
note = {CC BY},
}
RIS
TY - JOUR
TI - Bone Marrow Aplasia Under Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: A Rare and Unpredictable Complication.
AU - Morad Annasser
AU - Omar Halloumi
AU - Rida Fatima Ezzahra
AU - Salma Fares
PY - 2026
DA - 2026/09/28
JO - Cureus
DO - 10.7759/cureus.117060
UR - https://europepmc.org/article/MED/42953131
AB - Tyrosine kinase inhibitor (TKI)-induced bone marrow aplasia is a rare but potentially severe complication of chronic myeloid leukemia (CML). We report two cases occurring under imatinib and nilotinib in patients with chronic-phase CML. The first case, occurring six months after imatinib initiation, was characterized by severe bone marrow aplasia associated with gelatinous marrow transformation, a rare histological finding in TKI-treated CML. The second case, occurring two months after switching to nilotinib, evolved toward non-severe bone marrow aplasia, with complete hematologic recovery after treatment discontinuation. These observations illustrate the heterogeneity and unpredictability of this toxicity, which may occur across different TKI generations and levels of molecular response. Immediate TKI discontinuation remains essential, and any persistent pancytopenia should prompt early bone marrow evaluation to ensure a timely diagnosis and appropriate management.
SN - 2168-8184
ER -